Silo Pharma (SILO) Stock Tumbles 28% Following $4M Financing Announcement
Silo Pharma (SILO) stock dropped 28% to $5.57 after announcing a $4M private placement with warrants that could generate an additional $7.7M upon exercise. The post Silo Pharma (SILO) Stock Tumbles…
Read the full articleYou might also wanna read
Silo Pharma prices $11.7M at-the-market offering at $6.45 per share
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.
This big pharma stock looks attractive for income investors -- but it comes with some risk.

Oklo (NYSE: OKLO) Stock Price Tumbles 22% In June As DOE Loan Program Rattles SMR Investors
Oklo (NYSE: OKLO) shares dropped 21.8% in June, according to data from S&P Global Market Intelligence, even as the company racked up a strin
SpaceX stock drops 23% from peak, falls below IPO price after 16% plunge
Shares of Elon Musk’s SpaceX tech conglomerate plunged 16% Monday to close below their price on June 12, after the company’s massive initial
SpaceX stock drops 23% from peak, falls below IPO price after 16% plunge
Shares of Elon Musk’s SpaceX tech conglomerate plunged 16% Monday to close below their price on June 12, after the company’s massive initial
SpaceX stock drops 23% from peak, falls below IPO price after 16% plunge
Shares of Elon Musk’s SpaceX tech conglomerate plunged 16% Monday to close below their price on June 12, after the company’s massive initial

AstraZeneca Stock Tumbles 6% Following Late-Stage Heart Disease Drug Trial Failure
AstraZeneca stock fell 9% after its Wainua heart drug trial missed its primary goal, raising questions about management credibility.
Cue Biopharma to sell 1.418M shares at $33.21 in private placement
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F

Comments
Sign in to join the conversation.
No comments yet. Be the first.